Cannabis and Epilepsy: What the Research Shows on Seizure Control
The transition of medical cannabis from anecdotal reporting to a data-driven therapeutic category began with the FDA approval of Epidiolex. By establishing a purified CBD oral solution as a standard for treatment-resistant epilepsy, the medical community moved into clinical precision.
By Harrison
Clinical Benchmarks: FDA-Approved Efficacy
Data from randomized controlled trials (RCTs) serves as the foundation for modern CBD application. Pharmaceutical-grade CBD may support symptom management across three primary neurological indications:
- Dravet Syndrome: In a randomized controlled trial published in the New England Journal of Medicine (Devinsky et al., 2017), pharmaceutical-grade CBD produced a 39% median reduction in convulsive seizures compared to 13% in the placebo group.
- Lennox-Gastaut Syndrome (LGS): Separate RCTs (Devinsky et al., Lancet Neurology, 2018; Thiele et al., Lancet, 2018) showed CBD reduced drop seizures by approximately 37–44% compared to 17–25% for placebo.
- Tuberous Sclerosis Complex (TSC): Approval followed data showing a drop in seizure frequency.
Side effects are consistent: patients may experience somnolence (drowsiness), decreased appetite, and diarrhea.
The Mechanism of Action
Unlike THC, CBD does not rely on the CB1 and CB2 receptors that drive psychoactive responses. Instead, it operates through specific physiological pathways:
- GPR55 Modulation: CBD acts as an antagonist to GPR55 receptors, which may help regulate excessive excitatory signaling.
- TRPV1 Channel Desensitization: By interacting with vanilloid receptors, CBD helps support stable intracellular calcium levels.
- Stabilizing Neuronal Membranes: These processes may assist in quieting the electrical surges that trigger seizure activity.
Pharmaceutical CBD vs. Consumer Market CBD
Patients often confuse pharmacy-grade CBD with the broader consumer market. The differences are biological and regulatory.
| Metric | Epidiolex (Pharmaceutical) | Whole-Plant CBD (Consumer) |
|---|---|---|
| Composition | 99% pure CBD | Variable (CBD, THC, Terpenes) |
| Dosing Precision | Standardized 100 mg/mL | High batch-to-batch variability |
| Regulatory Oversight | FDA Monitored | State/Hemp-level oversight |
| Cost Structure | High (Insurance eligible) | Moderate (Out-of-pocket) |
Consumer-grade products rarely meet the Certificate of Analysis (COA) rigor necessary for medical epilepsy management. If you operate outside the pharmaceutical stream, you must demand transparent, third-party testing for heavy metals, pesticides, and solvents.
Critical Drug Interactions: The CYP450 Pathway
CBD is an inhibitor of the CYP450 liver enzyme system, which metabolizes roughly roughly half of commonly prescribed medications. Co-administration with Anti-Seizure Medications (ASMs) requires strict oversight.
- Clobazam (Onfi): CBD can increase the active metabolite of clobazam by 60–80%, which may lead to heavy sedation.
- Valproate (Depakote): Simultaneous use carries a risk of elevated liver enzymes (ALT/AST), necessitating routine blood work.
- Stiripentol and Topiramate: CBD changes the serum concentrations of these drugs, which often necessitates a recalibration of dosages.
THC and the Seizure Threshold
The role of THC in epilepsy remains complex. While some retrospective surveys suggest benefits, THC may act as a pro-convulsant in specific patient profiles.
- The Risk: High-THC products may lower the seizure threshold in some individuals, potentially triggering the events they are intended to prevent.
- Clinical Practice: Many practitioners prefer a 20:1 CBD-to-THC ratio or higher to support anticonvulsant activity while minimizing the risk of psychoactivity or increased seizure frequency.
Quality Control for Product Selection
If you navigate the consumer market, you should verify quality standards.
- Demand Batch-Specific COAs: Never purchase a product without a lab report that matches your specific batch. Verify that the CBD content on the bottle matches the lab result.
- Prioritize Solvent-Free Extraction: Favor CO2 extraction methods. Avoid products extracted with harsh butane or ethanol.
- Source Matters: Look for domestically grown, organic hemp to avoid the bioaccumulation of toxins from the soil.
- Consistency: Do not jump between brands. Different manufacturers use different terpene profiles and cannabinoid ratios; switching products can destabilize a patient’s seizure control.
Quantitative Dosing Protocols
In a clinical setting, dosing is calculated by body weight (mg/kg).
- Starting Phase: 2.5 mg/kg twice daily (5 mg/kg/day).
- Maintenance Phase: 5–10 mg/kg twice daily (10–20 mg/kg/day).
- Monitoring: Increases should be incremental and weekly, with a close eye on tolerance and efficacy.
For context, a 20 kg (44 lb) child requires a maintenance dose of 200–400 mg per day. Given that many consumer-grade bottles contain only 300–600 mg of CBD in the entire bottle, pharmaceutical-grade concentrations are often the most practical solution for long-term daily management.
Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.
Ready to find your strain?
Add your strains, pick your effects — we'll rank them.